Key result
Renin-angiotensin system blockade reduces cardiovascular and renal disease risk in overweight populations, but specific randomized trials in obesity-related hypertension are still needed.
Why the study?
Does renin-angiotensin system blockade reduce cardiovascular and renal disease risk in patients with obesity-related hypertension and cardiometabolic syndrome?
Population
Patients with obesity-related hypertension and cardiometabolic syndrome
Comparison
Renin-angiotensin system blockade vs Other classes of antihypertensive therapy
Design
Review
Authors
Loading...
Obesity-hypertension synergy magnifies CV/renal risk in cardiometabolic syndrome; leaves open need for targeted prognostic validation in prospective cohorts.
Does renin-angiotensin system blockade reduce cardiovascular and renal disease risk in patients with obesity-related hypertension and cardiometabolic syndrome?
Renin-angiotensin system blockade represents a promising therapeutic strategy to reduce cardiovascular, renal, and metabolic risks in patients with obesity-related hypertension.
Sharma et al. (2006) conducted a review in Hypertension associated with the cardiometabolic syndrome and obesity. Renin-angiotensin system (RAS) blockade was evaluated. Renin-angiotensin system blockade reduces cardiovascular and renal disease risk in overweight populations, but specific randomized trials in obesity-related hypertension are still needed.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: